HOME >> BIOLOGY >> NEWS
Mouse model advances understanding of synovial sarcoma

A mouse model for synovial sarcoma has enabled scientists to make tremendous progress toward understanding the origin and pathogenesis of this highly aggressive soft-tissue malignancy. The research, published in the April issue of the journal Cancer Cell, published by Cell Press, provides new information about the timing and environment required for initiation and progression of synovial sarcoma. The mouse model is also likely to serve as an invaluable resource for development of successful therapeutic strategies for this often lethal cancer.

Synovial sarcoma is associated with expression of a chimeric fusion protein called SYT-SSX. Dr. Mario R. Capecchi, from the Howard Hughes Medical Institute and the Department of Human Genetics at the University of Utah School of Medicine, and colleagues developed a mouse model that expresses human SYT-SSX in chosen target cells. Using this approach, the researchers discovered that, although it is named for its common proximity to limb joints, this tumor appears to arise from skeletal muscle precursor cells called myoblasts. Remarkably, expression of SYT-SSX in myoblasts was sufficient to induce synovial sarcoma with an astonishing 100% penetrance.

Use of a sophisticated conditional genetic technique allowed the researchers to control the timing of fusion protein expression so as to examine what happens when the protein is expressed at different stages of muscle development. Earlier expression of SYT-SSX disrupted normal development and was associated with embryonic lethality, while expression in more differentiated muscle cells induced significant muscle cell damage and death in the absence of tumor formation.

Further studies demonstrated that this mouse model of synovial sarcoma faithfully recapitulates human synovial sarcoma on multiple levels. As in the human cancer, tumors in the mice arise most commonly in close proximity to joints. The researchers speculate that the cartilage associa
'"/>

Contact: Erin Doonan
edoonan@cell.com
617-397-2802
Cell Press
9-Apr-2007


Page: 1 2

Related biology news :

1. Mouse FH knockout resembles human renal cell cancer
2. Mouse stem cell line advance suggests potential for IVF-incompetent eggs
3. Mouse model underestimates the critical role of Tyk2 in human immune system
4. Mouse DNA to aid biomedical research
5. Mouse strain with gene stutter will help leukemia research
6. Knockout Mouse Project
7. NIH launches Knockout Mouse Project
8. Mouse mimics chronic leukemia, will aid drug development
9. Mouse, frog and bird put Snail and Slug to different uses
10. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
11. Mouse to man: The story of chromosomes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/28/2017)... , Spanien, 27. Februar 2017  EyeLock LLC, ein ... wird seine erstklassige biometrische Lösung zur Iris-Erkennung ... mit X16 LTE auf dem Mobile World ... am Qualcomm-Stand in Halle 3, Stand 3E10, ... die Sicherheitsplattform Qualcomm Haven™ – eine Kombination ...
(Date:2/24/2017)...  EyeLock LLC, a leader of iris-based identity ... biometric solution on the latest Qualcomm® Snapdragon™ 835 ... World Congress 2017 (February 27 – March ... 3, Stand 3E10. The Snapdragon ... platform—a combination of hardware, software and biometrics ...
(Date:2/21/2017)... February 21, 2017 Der weltweite ... wachsen. Nach einem Gespräch mit mehr als 50 Vertretern aus ... zu überwinden gilt, um diese Prognose zu realisieren. ... ... Mobilisierung der finanziellen Mittel für die Biobank, die Implementierung ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... -- Research and Markets has announced the addition ... their offering. ... The Global Market for Bioproducts Should Reach $714.6 ... CAGR of 8.9%, This research report quantifies ... major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), ...
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... animal blood plasma products and derivatives market is fragmented due to the ... large players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, ... clear leader, these three companies, collectively, held more than 76% of ... ...
(Date:3/22/2017)... 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today ... (RGC), U.K. Biobank and GSK to generate genetic sequence data ... The initiative will enable researchers to gain valuable insights to ... wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
Cached News: